Reuters exclusive: Anthropic quietly built a wet lab in the Bay Area for drug discovery
dotey · x · 2026-09-20
Reuters reports Anthropic has quietly built a wet lab in the San Francisco Bay Area, extending its AI ambitions into real-world biology.
Key facts:
- Life sciences lead Eric Kauderer-Abrams confirmed the lab; final validation still requires real experiments, done partly in-house and partly with partners
- Recent moves: $400M stock acquisition of Coefficient Bio for drug discovery tooling, Novartis CEO Vas Narasimhan joining the board, the Claude Science software release, and a June announcement of a drug discovery program
- Hiring protein/nucleic-acid characterization experts; stated goal: "speed up life sciences by an order of magnitude"
- Focus: "undruggable" rare-disease targets and multi-specific antibodies (dual/trispecific) that AI handles well; preclinical only, no clinical trials — partly to reassure pharma clients like Genentech, BMS, and Novo Nordisk
- Context: comes ahead of a rumored $2T IPO, amid safety controversy including internal warnings about extinction risk and biosecurity misuse; Dario Amodei has personal stakes, having lost his father to a disease cured years later
- Comparison: Google's Isomorphic Labs has pushed back its clinical timeline; drug discovery remains a long, high-failure road.
More from Companies & People
- Replit's User Ops lead built an AI app to prioritize and route support tickets — amasad · 2026-11-04
- John Lewis's worst-reviewed Christmas ad: why it wants to stop cash gift cards — aakashgupta · 2026-11-04
- Datasite CTO on ditching in-house parsing: better parsing lifted recall 22% — AI Engineer · 2026-11-04
- Technical founders: as CEO, storytelling is the core job you can't skip — paigeinsf · 2026-11-04
- Andreessen: Agents Are Entering Enterprises as Chaos, Just Like PCs and Spreadsheets Did — Dan_Jeffries1 · 2026-11-04
- DeepMind, Cognition host bouldering social ahead of AI Engineer Code Summit — osanseviero · 2026-11-04